Invitation til præsentation af ALK’s årsrapport for 2024 onsdag den 19. februar 2025
12 févr. 2025 11h02 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) offentliggør sin årsrapport for 2024 om morgenen onsdag den 19. februar 2025. ALK afholder senere samme dag kl. 13.30 (CET) en præsentation for investorer og...
Invitation to the presentation of ALK’s annual report 2024 on Wednesday, 19 February 2025
12 févr. 2025 11h02 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) will publish its annual report for 2024 in the morning on Wednesday, 19 February 2025. Later on the same day, the company will host a presentation for investors...
ALK’s house dust mite tablet (ACARIZAX®) now recommended by NICE for use in the UK health system
30 janv. 2025 04h13 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the National Institute for Health and Care Excellence (NICE) has recommended the use of ACARIZAX® for the treatment of persistent, moderate to...
ALK – Finanskalender for regnskabsåret 2025
20 déc. 2024 11h09 HE
|
ALK Abello
Finanskalender 2025 for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22. januar 2025: Stilleperiode19. februar 2025: Offentliggørelse af årsrapport 202413. marts 2025 kl. 16.00:...
ALK – Financial calendar for the 2025 financial year
20 déc. 2024 11h09 HE
|
ALK Abello
2025 financial calendar for ALK (ALKB:DC / OMX: ALK B / AKBLF): 22 January 2025: Silent period 19 February 2025: Annual report...
Positive resultater fører peanut-tablet videre til fase II-udvikling
18 déc. 2024 06h51 HE
|
ALK Abello
ALKs peanut-tablet påvist at være sikker og veltolereret på tværs af flere forskellige doserUdviklingen går nu ind i fase II, hvor dosisvalg og effekt undersøgesDe første patienter i fase II vil snart...
Positive results advance peanut tablet to phase II development
18 déc. 2024 06h51 HE
|
ALK Abello
ALK’s peanut tablet shown to be safe and tolerable across multiple doses.Development now advances to phase II for dose finding and efficacy. First patients in phase II to receive first doses...
ACARIZAX® godkendt i Europa til behandling af yngre børn
12 déc. 2024 10h06 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) har i dag annonceret, at selskabets europæiske registreringsansøgning for ACARIZAX® (tabletvaccine mod husstøvmideallergi) hos børn i alderen fem til 11 år er blevet...
ACARIZAX® approved in Europe for treatment of young children
12 déc. 2024 10h06 HE
|
ALK Abello
ALK (ALKB:DC / OMX: ALK B) today announced that its European regulatory filing for ACARIZAX® (house dust mite sublingual allergy immunotherapy tablet) in young children aged five to 11 has been...
ALK’s pivotal phase 3 trial in children published in reputable scientific journal
27 nov. 2024 07h45 HE
|
ALK Abello
The reputable scientific journal, The Lancet Regional Health – Europe, has published robust results from ALK’s house dust mite sublingual allergy immunotherapy tablet (SLIT-tablet) phase 3 children...